Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 13, 2024Medicine InternationalOpen Access

Visnagin: A novel cardioprotective agent against anthracycline toxicity (Review)

View Full Paper
Ask AI
Bookmark
Share

Authors

OOOmar ObeidatAOAli ObeidatAOAbedallah Obeidat

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Obeidat et al. (2024) studied this question.

synapsesocial.com/papers/68e6a61fb6db6435876291cdhttps://doi.org/10.3892/mi.2024.161
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity2018 · 41 citations
  2. 2Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.2016 · 11 citations
  3. 3Novel Therapeutics for Anthracycline Induced Cardiotoxicity2022 · 49 citations
  4. 4Anthracycline Cardiotoxicity: From Bench to Bedside2008 · 456 citations
  5. 5Doxorubicin: The Good, the Bad and the Ugly Effect2009 · 1,514 citations